Pediatrics at CU School of Medicine is among the best in the nation! World-class pediatric residency program and research facilities. Department of Pediatrics, University of Colorado School of Medicine, Children's Hospital Colorado

A Multicenter, Randomized, Vehicle-Controlled Clinical Study to Examine the Efficacy and Safety of Atopiclair in the Management of Mild to Moderate Atopic Dermatitis in Adults
Principal Investigator: Mark Boguniewicz, MD
Source: Sinclair Pharmaceuticals
Term: 2004-present

A Six-Week Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Elidel Cream 1% in Patients with Mild to Moderate Chronic Hand Dermatitis, Followed by a Six-Week Open-Label Phase to Assess the Safety of Elidel Cream 1%
Principal Investigator: Mark Boguniewicz, MD
Source: Novartis Pharmaceuticals
Term: 2004-present

A Two-Stage Randomized, Open-Label, Parallel Group, Phase III Multicenter, 7-Month Study to Assess the Efficacy and Safety of Symbicort pMDI Administered Either as Fixed or as an Adjustable Regimen vs. a Fixed Regimen of Advair in Subjects 12 Years of Age or Older with Asthma
Principal Investigator: Mark Boguniewicz, MD
Source: AstraZeneca Pharmaceuticals
Term: 2003-2005

An Investigation of the Safety and Efficacy of Elidel 1% Cream in Atopic Disease Modification, Assessed in a Three-Year Randomized, Double-Blind Vehicle-Controlled Phase to Evaluate the Effects of Atopic Dermatitis in Infants, and a Two-Three-Year Open-Label Phase to Evaluate the Effect of Early Intervention vs. Delayed Intervention with Elidel on the Incidence of Asthma in Children
Principal Investigator: Mark Boguniewicz, MD
Source: Novartis Pharmaceuticals
Term: 2003-present

An Investigation of the Safety and Efficacy of Elidel 1% Cream in an Exploratory, Double-Blind, Randomized, Vehicle-Controlled, Paired Study to Evaluate the Efficacy and Safety of Concomitant Use of Pimecrolimus Cream 1% and Fluticasone Propionate Cream 0.05% in Patients with Severe Lesions of Atopic Dermatitis
Principal Investigator: Mark Boguniewicz, MD
Source: Novartis Pharmaceuticals
Term: 2004-present

Immune Response to Varicella Vaccination in Subjects with Atopic Dermatitis Compared to Nonatopic Controls
Principal Investigator: Mark Boguniewicz, MD
Source: National Institute of Allergy and Infectious Diseases, Atopic Dermatitis and Vaccinia Network Clinical Studies Consortium
Amount: $20,723,556
Term: 2005-2009

Cell Culture Core: Ether Lipids, Eicosanoids and Lung Cell Pathophysiology
Co-Investigator: Donna L. Bratton, MD
Program Director: Peter M. Henson, PhD
Source: National Institutes of Health - PO1 HL34303
Amount: $117,894/yr
Term: 2000-2005

Defective Phosphatidylserine Exposure in Eutrophil Apoptosis in Chronic Granulomatous Disease
Principal Investigator: Donna L. Bratton, MD
Source: National Institutes of Health - R01 AI058228
Amount: $175,000/yr
Term: 2003-2007

Phospholipid Signaling from Apoptotic Cells, Project 3
Program Project Grant: Ether Lipids, Eicosanoids, and Lung Cell Pathophysiology
Program Director: Christina C. Leslie, PhD
Principal Investigator: Donna L. Bratton, MD
Source: National Institutes of Health - HL34303
Amount: $251,822/yr
Term: 2005-2010

Age-Dependent Increases in Airway Responsiveness by RSV
Principal Investigator: Erwin W. Gelfand, MD
Source: National Institutes of Health - R01 HL6 1005
Amount: $198,071/yr
Term: 1999-2008

Airway Function: The Role of T-Cells
Principal Investigator: Willi Born, PhD
Co-Investigator: Erwin W. Gelfand, MD
Source: National Institutes of Health - 1U01 HL65899-01
Amount: $203,656/yr
Term: 2000-2009

Inflammation, Airway Reactivity and Asthma
Project 2: Role of T Lymphocytes in Airway Hyperresponsiveness
Principal Investigator: Erwin W. Gelfand, MD
Co-Investigator: Azzeddine Dakhama, PhD
Source: National Institutes of Health - HL-36577
Amount: $243,791
Term: 2001-2006

Inflammation, Airway Reactivity and Asthma
Principal Investigator: Erwin W. Gelfand, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - HL36577
Term: 2001-2006

• Mechanisms in Steroid-Resistant Asthma
  Principal Investigator: Erwin W. Gelfand, MD
  Co-Investigator: Donald Y. M. Leung, MD, PhD
  Amount: $246,061/yr
  
• Role of T Lymphocytes in Airway Hyperresponsiveness
  Principal Investigator: Erwin W. Gelfand, MD
  Amount: $258,638/yr
  
• Eosinophil, Eicosanoid Biosynthesis and Metabolism
  Principal Investigator: Erwin W. Gelfand, MD
  Co-Investigator: Robert C. Murphy, PhD
  Amount: $197,180/yr
  

Inhalation of Particulate Matter Alters the Allergic Airway Response to Inhaled Allergen
Principal Investigator: Erwin W. Gelfand, MD
Source: Environmental Protection Agency - R825702
Amount: $235,043/yr
Term: 1997-2008

Pharmacogenetics Research Network and Database
Principal Investigator: Scott Weiss, MD
Principal Investigator (Denver site): Erwin W. Gelfand, MD
Source: National Institutes of Health - 1U01 HL65899-01
Amount: $214,337/yr
Term: 2000-2005

Training Program in Pediatric Immunology
Principal Investigator: Erwin W. Gelfand, MD
Source: National Institutes of Health - T32 A107365
Amount: $158,839/yr
Term: 1990-2005

Institutional Review Board Assessment and Education Project
Principal Investigator: Richard B. Johnston, Jr., MD
Source: National Institutes of Health, National Center for Research Resources
Amount: $150,000
Term: 2002-2005

Neuroimmune Interactions in Developing Airways
Principal Investigator: Gary L. Larsen, MD
Co-Investigator: Azzeddine Dakhama, PhD
Source: National Institutes of Health - RO1 HL-67818
Amount: $225,000
Term: 2002-2006

The Atopic Dermatitis Vaccinia Network: Animal Studies Consortium
Principal Investigator: Raif Geha, MD, PhD
Co-Investigator: Donald Y. M. Leung, MD, PhD
Source: National Institutes of Health, National Institutes of Allergy and Infectious Diseases - HHSN266200400030C, ADB Contract #N01-AI-40030
Amount: $10,031,776
Term: 2004-2009

The Atopic Dermatitis Vaccinia Network: Clinical Studies Consortium
Principal Investigator: Donald Y. M. Leung, MD, PhD
Source: National Institutes of Health, National Institutes of Allergy and Infectious Diseases - HHSN26620040029C, ADB Contract #N01-AI-40029
Amount: $20,723,556
Term: 2004-2009

Effect of Pimecrolimus on T-Cell Responses in Atopic March
Principal Investigators: Jonathan M. Spergel, MD - Children's Hospital of Philadelphia (CHOP), and Hugh A. Sampson, MD - Mt. Sinai
Denver Site Leader: Donald Y. M. Leung, MD, PhD
Source: National Institutes of Health, National Institutes of Allergy and Infectious Diseases - 1R01AI62698
Amount: $708,721
Term: 2005-2009

Immunology of Peanut Allergy and Its Treatment: A Prototype
Principal Investigator: Hugh A. Sampson, MD - Mt. Sinai
Denver Site Leader: Donald Y. M. Leung, MD, PhD
Source: National Institutes of Health, National Institutes of Allergy and Infectious Diseases - 1 U19 AI066738-01
Amount: $16,430,158
Term: 2005

Immunomodulation of Vaccinia-Induced Antimicrobial Peptides
Principal Investigator: Donald Y. M. Leung, MD, PhD
Source: National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases - 5 R21 AR051634-02
Amount: $156,600
Term: 2004-2006

Pediatric Clinical Translational Research Center
Principal Investigator: Principal Investigator: Richard Krugman, MD
Associate Program Director: Donald Y. M. Leung, MD, PhD
Source: National Institutes of Health, National Center for Research Resources - 3M01RR00051
Amount: $8,500,000
Term: 2001-2006

Role of Antimicrobial Peptides in Host Defense Against Vaccinia Virus
Principal Investigator: Donald Y. M. Leung, MD, PhD
Co-Investigator: Mark Boguniewicz, MD
Source: National Institute of Allergy and Infectious Disease, Atopic Dermatitis and Vaccinia Network Clinical Studies Consortium
Amount: $20,723,556
Term: 2005-2009

Role of Bacterial Toxins in Human Skin Diseases
Principal Investigator: Donald Y. M. Leung, MD, PhD
Source: National Institute of Arthritis and Musculoskeletal and Skin Diseases - 1RO1 AR41256
Amount: $1,125,000
Term: 2005-2010

Role of Bacterial Toxins in Human Skin Diseases
Principal Investigator: Donald Y. M. Leung, MD, PhD
Co-Investigator: Mark Boguniewicz, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - 5 R01 AR-41256
Amount: $1,544,400
Term: 2005-2010

Role of IL-31 in Atopic Dermatitis
Principal Investigator: Donald Y. M. Leung, MD, PhD
Source: Zymogenetics
Amount: $102,000
Term: 2004-2005

Role of Xolair in Peanut Allergy
Principal Investigator: Donald Y. M. Leung, MD, PhD
Source: Genentech, Inc. - Protocol Q2788G
Amount: $155,414
Term: 2004-2006

Endotoxin and Asthma Prevention in Young Children
Principal Investigator: Andrew H. Liu, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute
Amount: $577,182/yr
Term: 2001-2006

Immune Pathogenesis and Prevention of Asthma in Young Children
Principal Investigator: Andrew H. Liu, MD
Source: National Institutes of Health, Pediatric Clinical Translational Research Center - M01 RR00051, NJ137
Amount: $125,000/yr
Term: 1998-2005

Immunology of Peanut Allergy and its Treatment: A Prototype (IPAT)
Principal Investigator: Hugh Sampson, MD
Co-Investigator: Andrew H. Liu, MD
Amount: $16,430,158
Source: National Institutes of Health
Term: 2005-2010

Inner City Asthma Consortium
Principal Investigator: William Busse, MD
Co-Investigator: Andrew H. Liu, MD
Source: National Institutes of Health
Term: 2002-2008

Prevention of Chronic Asthma: Age 7 Follow-up
Principal Investigator: Mary Klinnert, PhD
Co-Investigators: Andrew H. Liu, MD, and Bruce Bender, PhD
Source: National Institutes of Health - R18 AI41137
Amount: $175,000
Term: 2002-2006

Prevention of Chronic Asthma in Young Children
Principal Investigator: Mary D. Klinnert, MD
Co-Investigator: Andrew H. Liu, MD
Source: National Institutes of Health, National Institutes of Allergy and Infectious Diseases
Term: 1997-2006

Study of Allergen, Genetics and Endotoxin (SAGE)
Principal Investigator: Lee Newman, MD
Co-Investigator: Andrew H. Liu, MD
Source: National Institutes of Health
Amount: $225,000
Term: 2005-2010

Air Pollution Health Effects: A Source-Oriented Approach
Principal Investigator: Sverre Vedal, MD
Co-Investigator: Nathan Rabinovitch, MD
Source: National Institutes of Health - R01ES012197
Amount: $1,800,000
Term: 2004-2009

Air Pollution, LTE4, and Decreased Asthma Control: Prevention with Montelukast
Principal Investigator: Erwin W. Gelfand, MD
Co-Investigator: Nathan Rabinovitch, MD
Source: Merck - 31359
Amount: $120,000
Term: 2005-2006

Health Effects of Environmental Tobacco Smoke (ETS) in Urban Poor Minority Children with Asthma
Principal Investigator: Nathan Rabinovitch, MD
Source: Colorado Tobacco Research Project
Amount: $250,000/yr
Term: 2002-2005

Health Effects of Personal Exposure to Particulate in Children with Asthma
Principal Investigator: Nathan Rabinovitch, MD
Source: Environmental Protection Agency
Amount: $202,211/yr
Term: 1999-2005

Impact of Poor Air Quality on Severity of Childhood Asthma
Principal Investigator: Erwin W. Gelfand, MD
Co-Investigator: Nathan Rabinovitch, MD
Source: Thrasher Research Fund - 02816
Amount: $120,000/yr
Term: 2002-2006

Personal Exposure to Particulate Air Pollution in Childhood Asthma
Principal Investigator: Nathan Rabinovitch, MD
Source: Environmental Protection Agency - R825702
Amount: $150,000/yr
Term: 1999-present

Asthma Clinical Research Network
Co-Investigators: Stanley J. Szefler, MD, and Richard Martin, MD
Source: National Heart, Lung and Blood Institute - HL 51834
Amount: $2,500,000
Term: 2003-2008

Childhood Asthma Management Program Continuation Study
Principal Investigator: Stanley J. Szefler, MD
Co-Investigator: Ronina A. Covar, MD
Source: National Institutes of Health
Amount: $809,822
Term: 2003-2007

Childhood Asthma Management Program Continuation Study/Phase 2
Principal Investigator: Stanley J. Szefler, MD
Source: National Heart, Lung and Blood Institute
Amount: $809,822
Term: 2004-2008

Childhood Asthma Research and Education Network
Principal Investigator: Stanley J. Szefler, MD
Co-Investigator: Ronina A. Covar, MD
Source: National Institutes of Health
Amount: $8,317,722
Term: 1999-2009

Childhood Asthma Research and Education Network
Principal Investigator: Stanley J. Szefler, MD
Source: National Heart Lung and Blood Institute
Amount: $3,500,000
Term: 2004-2009

Childhood Asthma Research and Education (CARE) Network
Principal Investigator: Stanley J. Szefler, MD
Co-Investigator: Marzena E. Krawiec, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - U10-HL64288
Amount: $883,010
Term: 2004-2009

Inner City Asthma Consortium
Principal Investigator: Stanley J. Szefler, MD
Co-Investigator: Ronina A. Covar, MD
Source: National Institutes of Allergy and Infectious Disease
Amount: $996,177
Term: 2002-2006

Inner City Asthma Consortium
Principal Investigator (Denver site): Stanley J. Szefler, MD
Source: National Institutes of Allergy and Infectious Diseases
Amount: $6,000,000
Term: 2002-2008

Evaluation of a Nutritional Formula for Asthma Intervention in Children
Principal Investigator: Stanley J. Szefler, MD
Source: Ross Pharmaceuticals
Amount: $1,100,000
Term: 2004-2006

Biochemical Basis of Ozone Toxicity
Principal Investigator: Carl W. White, MD
Source: Environmental Protection Agency
Amount: $90,000/yr
Term: 2004-2005

Cigarette Smoke, Oxidants and S-Adenosylmethionine
Principal Investigator: Carl W. White, MD
Source: Colorado Tobacco Research Program
Amount: $468,253
Term: 2003-2005

Hypoxia-Inducible Factors in Bronchopulmonary Dysplasia
Principal Investigator: Carl W. White, MD
Source: National Institutes of Health - 5 U01 HL056263
Amount: $225,000/yr
Term: 2003-2007

Lung Epithelial Cell Survival Signaling in Ozone in Cystic Fibrosis and Normals
Principal Investigator: Carl W. White, MD
Source: National Institutes of Health - 1 RO1 ES014448-01
Amount: $213,750/yr
Term: 2005-2010

Mechanisms of Particulate Toxicity - Ozone Exposure Core
Overall Principal Investigator: Robert J. Mason, MD
Project Principal Investigator: Carl W. White, MD
Source: Environmental Protection Agency
Amount: $83,840
Term: 2005-2006

Mechanisms of Sulfur Mustard Toxicity to Lung
Principal Investigator: Brian Day, PhD
Co-Investigator: Carl W. White, MD
Source: National Institutes of Health Supplement
Amount: $45,000/yr
Term: 2005-2006

A Multicenter, Randomized, Vehicle-Controlled Clinical Study to Examine the Efficacy and Safety of Atopiclair in the Management of Mild to Moderate Atopic Dermatitis in Adults
Principal Investigator: Mark Boguniewicz, MD
Source: Sinclair Pharmaceuticals
Term: 2004-present

A Phase III, Randomized, Double-Blind Study Comparing Twice Daily FK506 Cream 0.03% vs. Cream Vehicle in the Treatment of Atopic Dermatitis in Pediatric Patients
Principal Investigator: Mark Boguniewicz, MD
Source: Fujisawa USA, Inc.
Term: 2003-2004

A Six-Week Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Elidel Cream 1% in Patients with Mild to Moderate Chronic Hand Dermatitis, Followed by a Six-Week Open-Label Phase to Assess the Safety of Elidel Cream 1%
Principal Investigator: Mark Boguniewicz, MD
Source: Novartis Pharmaceuticals
Term: 2004-present

A Two-Stage Randomized, Open-Label, Parallel Group, Phase III Multicenter, 7-Month Study to Assess the Efficacy and Safety of Symbicort pMDI Administered Either as Fixed or as an Adjustable Regimen vs. a Fixed Regimen of Advair in Subjects 12 Years of Age or Older with Asthma
Principal Investigator: Mark Boguniewicz, MD
Source: AstraZeneca Pharmaceuticals
Term: 2003-2005

An Investigation of the Safety and Efficacy of Elidel 1% Cream in Atopic Disease Modification, Assessed in a Three-Year Randomized, Double-Blind Vehicle-Controlled Phase to Evaluate the Effects of Atopic Dermatitis in Infants, and a Two-Three-Year Open-Label Phase to Evaluate the Effect of Early Intervention vs. Delayed Intervention with Elidel on the Incidence of Asthma in Children
Principal Investigator: Mark Boguniewicz, MD
Source: Novartis Pharmaceuticals
Term: 2003-present

An Investigation of the Safety and Efficacy of Elidel 1% Cream in an Exploratory, Double-Blind, Randomized, Vehicle-Controlled, Paired Study to Evaluate the Efficacy and Safety of Concomitant Use of Pimecrolimus Cream 1% and Fluticasone Propionate Cream 0.05% in Patients with Severe Lesions of Atopic Dermatitis
Principal Investigator: Mark Boguniewicz, MD
Source: Novartis Pharmaceuticals
Term: 2004-present

The Role of IL-31 in Atopic Dermatitis
Principal Investigator: Mark Boguniewicz, MD
Source: ZymoGenetics
Amount: $102,000
Term: 2004-2005

Regulation of Membrane Phospholipid Distribution and Mediator Translocation by Scramblase: Ether Lipids, Eicosanoids and Lung Cell Pathophysiology (Project 4)
Principal Investigator: Donna L. Bratton, MD
Program Director: Peter M. Henson, PhD
Source: National Institutes of Health - PO1 HL34303
Amount: $214,854/yr
Term: 2000-2005

Defective Phosphatidylserine Exposure in Eutrophil Apoptosis in Chronic Granulomatous Disease
Principal Investigator: Donna L. Bratton, MD
Source: National Institutes of Health - R01 AI058228
Amount: $175,000/yr
Term: 2003-2007

Cell Culture Core: Ether Lipids, Eicosanoids and Lung Cell Pathophysiology
Co-Investigator: Donna L. Bratton, MD
Program Director: Peter M. Henson, PhD
Source: National Institutes of Health - PO1 HL34303
Amount: $117,894/yr
Term: 2000-2005

Defective Phosphatidylserine Exposure During Neutrophil Apoptosis in Chronic Granulomatous Disease Inhibits Phagocytic Recognition and Engulfment and Results in Enhanced Inflammation
Principal Investigator: Donna L. Bratton, MD
Source: Immune Deficiency Foundation
Amount: $47,000
Term: 2003-2004

Inflammation, Airways Reactivity and Asthma
Principal Investigator: Erwin W. Gelfand, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - HL-36577
Term: 2001-2006

• Mechanisms in Steroid-Resistant Asthma
  Principal Investigator: Erwin W. Gelfand, MD
  Co-Investigator: Donald Y. M. Leung, MD, PhD
  Amount: $238,893/yr
  
• Role of T Lymphocytes in Airway Hyperresponsiveness
  Principal Investigator: Erwin W. Gelfand, MD
  Amount: $251,104/yr
  
• Eosinophil, Eicosanoid Biosynthesis and Metabolism
  Principal Investigator: Erwin W. Gelfand, MD
  Co-Investigator: Robert C. Murphy, PhD
  Amount: $191,437/yr
  

Inhalation of Particulate Matter Alters the Allergic Airway Response to Inhaled Allergen
Principal Investigator: Erwin W. Gelfand, MD
Source: Environmental Protection Agency - R825702
Amount: $235,043/yr
Term: 1997-2004

Regulation of Mast Cell Cytokine Production
Principal Investigator: Erwin W. Gelfand, MD
Source: National Institutes of Health - R01 AL 42246
Amount: $225,000/yr
Term: 1998-2004

Pharmacogenetics Research Network and Database
Principal Investigator: Scott Weiss, MD
Principal Investigator: Erwin W. Gelfand, MD (Denver site)
Source: National Institutes of Health - 1U01 HL65899-01
Amount: $214,337/yr
Term: 2000-2005

Regulation of Airway Function: The Role of T-Cells
Principal Investigator: Willi Born, PhD
Co-Investigator: Erwin W. Gelfand, MD
Source: National Institutes of Health - 1U01 HL65899-01
Amount: $203,656/yr
Term: 2000-2005

Age-Dependent Increases in Airway Responsiveness by RSV
Principal Investigator: Erwin W. Gelfand, MD
Co-Investigator: Azzeddine Dakhama, PhD
Source: National Institutes of Health - RO1 HL-61005
Amount: $198,071/yr
Term: 1999-2009

Training Program in Pediatric Immunology
Principal Investigator: Erwin W. Gelfand, MD
Source: National Institutes of Health - T32 A107365
Amount: $158,839/yr
Term: 1990-2005

Institutional Review Board Assessment and Education Project
Principal Investigator: Richard B. Johnston, Jr., MD
Source: National Institutes of Health, National Center for Research Resources
Amount: $150,000
Term: 2002-2005

Neuroimmune Interactions in Developing Airways
Principal Investigator: Gary L. Larsen, MD
Co-Investigator: Azzeddine Dakhama, PhD
Source: National Institutes of Health - RO1 HL-67818
Amount: $225,000
Term: 2002-2006

General Clinical Research Center
Principal Investigator: Richard D. Krugman, MD
Co-Investigator: Donald Y. M. Leung, MD, PhD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - 5M1RR00052
Amount: $893,938
Term: 2001-2006

Pathogenesis and Etiology of Kawasaki Syndrome
Principal Investigator: Donald Y. M. Leung, MD, PhD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - 5 R01 HL37260-12
Amount: $785,421
Term: 1999-2004

Role of Bacterial Toxins in Human Skin Diseases
Principal Investigator: Donald Y. M. Leung, MD, PhD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - 5 R01 AR-41256
Amount: $141,000/yr
Term: 1992-2005

Endotoxin and Asthma Prevention in Young Children
Principal Investigator: Andrew H. Liu, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - K23 HL04272
Amount: $577,182/yr
Term: 2001-2006

Exhaled Breath Condensates Protocol
Principal Investigator: Andrew H. Liu, MD
Source: National Institutes of Health, National Institute of Allergic and Infectious Diseases - N01 AI25946
Amount: $240,725/yr
Term: 2003-2004

Immune Pathogenesis and Prevention of Asthma in Young Children
Principal Investigator: Andrew H. Liu, MD
Source: National Institutes of Health, General Clinical Research Center - M01 RR00051, NJ137
Amount: $125,000/yr
Term: 1998-2005

Endotoxin and Asthma Prevention in Young Children
Principal Investigator: Andrew H. Liu, MD
Source: National Institutes of Health, National Institute of Heart, Lung, and Blood Institute - K23-HL-04272-01A1
Amount: $122,418/yr
Term: 2003-2004

Prevention of Chronic Asthma in Young Children
Principal Investigator: Mary D. Klinnert, PhD
Co-Investigator: Andrew H. Liu, MD
Source: National Institutes of Health, National Institute of Allergic and Infectious Diseases - R18 AL41137
Term: 1997-2005

Health Effects of Environmental Tobacco Smoke (ETS) in Urban Poor Minority Children with Asthma
Principal Investigator: Nathan Rabinovitch, MD
Source: Colorado Tobacco Research Project
Amount: $250,000/yr
Term: 2002-2005

Impact of Poor Air Quality on Severity of Childhood Asthma
Principal Investigator: Nathan Rabinovitch, MD
Source: Thrasher Research Fund
Amount: $250,000/yr
Term: 2002-2005

Personal Exposure to Particulate Air Pollution in Childhood Asthma
Principal Investigator: Nathan Rabinovitch, MD
Source: Environmental Protection Agency
Amount: $210,000/yr
Term: 2002-2006

Health Effects of Personal Exposure to Particulate in Children with Asthma
Principal Investigator: Nathan Rabinovitch, MD
Source: Environmental Protection Agency
Amount: $202,211/yr
Term: 1999-2005

Childhood Asthma Research and Education Network
Principal Investigator: Stanley J. Szefler, MD
Co-Investigator: Ronina A. Covar, MD
Source: National Heart, Lung and Blood Institute - HL64288
Amount: $600,000/yr
Term: 1999-2004

Asthma Clinical Research Network
Principal Investigator: Richard Martin, MD
Co-Investigator: Stanley J. Szefler, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - HL 51834
Amount: $600,000/yr
Term: 2003-2008

Cockroach Allergen Extract Standardization Study
Principal Investigator: Stanley J. Szefler, MD
Co-Investigator: Andrew H. Liu, MD
Source: National Institutes of Health, National Institute of Allergic and Infectious Diseases - N01 AI25946
Amount: $322,000/yr
Term: 2003-2004

Inner City Asthma Consortium
Principal Investigator: Stanley J. Szefler, MD
Co-Investigator: Ronina A. Covar, MD
Source: National Institutes of Health, National Institute of Allergy and Infectious Diseases - N01 AI25946
Amount: $300,000/yr
Term: 2002-2008

Pediatric Pharmacology Research Unit Network
Principal Investigator: Stanley J. Szefler, MD
Source: National Institutes of Health, National Institute of Child Health and Human
Development - HD37237
Amount: $272,000/yr
Term: 1999-2004

Inner City Asthma Consortium
Principal Investigator: Stanley J. Szefler, MD
Co-Investigator: Andrew H. Liu, MD
Source: National Institutes of Health, National Institute of Allergic and Infectious Diseases - N01 AI25946
Amount: $158,000
Term: 2003-2004

Childhood Asthma Management Program
Principal Investigator: Stanley J. Szefler, MD
Co-Investigator: Ronina A. Covar, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - N01 HL16048
Amount: $132,627/yr
Term: 1991-2004

Cigarette Smoke, Oxidants and S-Adenosylmethionine
Principal Investigator: Carl W. White, MD
Source: Colorado Tobacco Research Program
Amount: $468,253
Term: 2003-2005

Hypoxia-Inducible Factors in Bronchopulmonary Dysplasia
Principal Investigator: Carl W. White, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute
Amount: $230,831/yr
Term: 2003-2007

Biochemical Basis of Ozone Toxicity
Principal Investigator: Carl W. White, MD
Source: Environmental Protection Agency
Amount: $90,000/yr
Term: 2004-2005

Head CT in the Evaluation of 1st Afebrile Seizures
Principal Investigator: Lalit Bajaj, MD, MPH
Co-Investigators: Mark G. Roback, MD, Louis C. Hampers, MD, MBA, Carol Okada, MD, and Rebecca Fastle, MD
Term: 2000-2004

Postreduction Management of Intussusception
Principal Investigator: Lalit Bajaj, MD, MPH
Co-Investigators: Mark G. Roback, MD, and Shayne Bland, MSc
Term: 2000-2002

Emergency Medical Services for Children Partnership Grant
Principal Investigator: F. Keith Battan, MD
Source: US Department of Health and Human Services, Maternal and Child Health Bureau -
FLAEMS01-00250
Amount: $122,000
Term: 2000-2001

L.O.C.O. (Latinos Overcoming Cultural Obstacles) "Needs Assessment for The Children's Hospital"
Principal Investigator: Sonja Burbano-O'Leary, MD
Co-Investigator: Louis C. Hampers, MD, MBA
Source: Colorado Chapter of the American Academy of Pediatrics
Amount: $3,000
Term: 2001

The Truth about Language Barriers
Principal Investigator: Sonja Burbano-O'Leary, MD
Co-Investigators: Louis C. Hampers, MD, MBA, and Stephen Federico, MD
Source: Colorado Chapter of the American Academy of Pediatrics
Amount: $3,000
Term: 2001-ongoing

Jungle Mobile: A Mobile Injury Prevention Project for Children
Principal Investigator: Kathryn D. Emery, MD
Co-Investigators: Allison Hawkes, MD, MS, Theresa Rapstine, RN, and Victoria Cassenbaugh, RN
Term: 1998-ongoing

A Screening Tool for the Detection of Child Abuse in the Emergency Department Setting
Joint Project with the Child Advocacy Protection Team
Principal Investigator: Kathryn D. Emery, MD
Term: 2001

Seat Belt and Car Safety Seat Use in SUVs
Primary Investigator: Kathryn D. Emery, MD
Co-Investigators: Lisa Hardin Van Bramer, MD, and Kevin Raines, MD
Source: National Highway Traffic Safety Administration - STNH22-01-H-05-257
Amount: $350,000
Term: 2001-2003

Childhood Injury Prevention Concerns of Migrant and Seasonal Farm Workers in Weld County
Principle Investigator: Kathryn D. Emery, MD
Co-Investigator: S. Glenn Faries, MD
Source: Colorado Injury Control Research Center
Amount: $15,000
Term: 2002-2003

Domestic Violence Policies in Pediatric Emergency Departments
Principle Investigator: Kathryn D. Emery, MD
Co-Investigators: Sheila Sullivan, MD, Andrew P. Sirotnak, MD, and Stephanie Stronks-Knapp, MD
Term: 2002-ongoing

Development of an Injury-Free Coalition for Kids
Principal Investigator: S. Glenn Faries, MD
Co-Investigator: Kathryn D. Emery, MD
Term: 2001-ongoing

Resident Education in the Emergency Department
Principal Investigator: S. Glenn Faries, MD
Term: 2002-ongoing

Need for Atropine for Emergent Pediatric Intubations
Principal Investigator: Rebecca Fastle, MD
Co-Investigator: Mark G. Roback, MD
Term: 1999-ongoing

Resuscitation Teaching at Primary Care Centers
Principal Investigator: Margaret Ferguson, MD
Co-Investigator: Mark G. Roback, MD
Term: 1998-ongoing

Utility of Anaerobic Blood Cultures in a Pediatric Emergency Department
Principal Investigator: Stephen Freedman, MD
Co-Investigator: Genie E. Roosevelt, MD, MPH
Term: 2001-2003

PEM Collaborative Research Committee, Cerebral Edema and DKA
Principal Investigator: Nicole Glaser, MD
Co-Investigator: Mark G. Roback, MD
Term: 1998-2001

Comparison of Oral Prednisone vs. Dexamethasone in Pediatric Asthma
Principal Investigator: Richard A. Greenberg, MD
Co-Investigators: Genie E. Roosevelt, MD, MPH, and Gwendolyn S. Kerby, MD
Term: 2002-ongoing

Peak Flow vs. Spirometry in Acute Asthma
Principal Investigator: David Gutglass, MD
Co-Investigator: Louis C. Hampers, MD, MBA
Term: 1997-ongoing

A.C.C.E.S.S. for Latinos: After-Hours Call Center and Extended Spanish Service
Principal Investigator: Louis C. Hampers, MD, MBA
Co-Investigators: Lauren Clark, PhD, RN, and Stephen Berman, MD
Term: 2001-2002

The Impact of Interpreters on Resource Utilization in a Pediatric Emergency Department
Principal Investigator: Louis C. Hampers, MD, MBA
Co-Investigator: Jennifer McNulty, MD
Term: 1999-2002

Physician-Based Practice Pattern Variations in the Management of AGE
Principal Investigator: Louis C. Hampers, MD, MBA
Co-Investigator: Elizabeth Powell, MD, MPH
Term: 2001-ongoing

Practice Variation in the Management of Croup
Principal Investigator: Louis C. Hampers, MD, MBA
Co-Investigators: S. Glenn Faries, MD, and Steven R. Poole, MD
Term: 1999-2002

Regional After-Hours Urgent Care Provided by a Tertiary Children's Hospital
Principal Investigator: Louis C. Hampers, MD, MBA
Co-Investigators: S. Glenn Faries, MD, and Steven R. Poole, MD
Term: 2001-2002

Booster Seat Project
Principal Investigator: Lisa Hardin Van Bramer, MD
Co-Investigator: Kathryn D. Emery, MD
Source: Emergency Medical Services and Kiwanis Pediatric Trauma Institute
Amount: $18,000
Term: 2001-2002

Association of Influenza with Bacterial Tracheitis
Principal Investigator: Ron L. Kaplan, MD
Co-Investigators: Mark G. Roback, MD, and Peggy Kelly, MD
Term: 2002-ongoing

Safety, Tolerability and Efficacy Study of Levalbuterol and Racemic Albuterol in Pediatric Patients Birth to 48 Months Old with Reactive Airways Disease in an Acute Setting
Principal Investigator: Gwendolyn S. Kerby, MD
Co-Investigator: S. Glenn Faries, MD
Term: 2001-2002

Effect of Ondansetron on Ketamine Sedation-Associated Vomiting
Principal Investigator: William T. Langston, MD
Co-Investigators: Joseph E. Wathen, MD, and Mark G. Roback, MD
Source: The Children's Hospital Research Institute
Amount: $5,000
Term: 2002-ongoing

Effect of Medical Spanish Classes on Satisfaction of Hispanic Patients in Pediatric Emergency Department
Principal Investigator: Suzanne Mazor, MD
Co-Investigators: Vidya Chande, MD, Louis C. Hampers, MD, MBA, and Steven Krug, MD
Term: 2000-2002

Interpretation of Traumatic Lumbar Punctures: Who Can Go Home?
Principal Investigator: Suzan Mazor, MD
Co-Investigators: Jennifer McNulty, MD, and Genie E. Roosevelt, MD, MPH
Term: 2001-ongoing

How Is Emergency Department Decision-Making Affected by the Existence of Reliable Follow-Up?
Principal Investigator: Jennifer McNulty, MD
Co-Investigators: Louis C. Hampers, MD, MBA, and Steven Krug, MD
Term: 1999-2001

Decision Rules for Obtaining Radiographs in Pediatric Knee Injuries
Principal Investigator: Brian Moore, MD
Co-Investigators: Louis C. Hampers, MD, MBA, and Kathryn Emery, MD
Term: 1998-ongoing

Indications for Knee Radiographs in Pediatric Patients with Acute Knee Injuries/Validation of a Clinical Decision Rule
Principal Investigator: Brian Moore, MD
Co-Investigators: Carol Turner, MD, and Kathryn D. Emery, MD
Term: 2000-ongoing

Correlation of Hemolysis with Facticous Hyperkalemia
Principal Investigator: Heather Owens, MD
Co-Investigator: Louis C. Hampers, MD, MBA
Term: 2002-ongoing

Acute Complication of Type 1 Diabetes in Children
Primary Investigator: Arleta B. Rewers, MD, PhD
Co-Investigators: Mark G. Roback, MD, and Joan P. Bothner, MD
Term: 2001-ongoing

Childhood Pedestrian Injuries
Primary Investigator: Arleta B. Rewers, MD, PhD
Term: 2002-ongoing

Femur Fractures and Associated Injuries
Principal Investigator: Arleta B. Rewers, MD, PhD
Co-Investigators: Kathryn D. Emery, MD, and F. Keith Battan, MD
Term: 2000-ongoing

Are Chest X-Rays Required for all First-Time Wheezers?
Principal Investigator: Mark G. Roback, MD
Co-Investigators: Mark E. Anderson, MD, and John D. Strain, MD
Term: 1998-ongoing

Comparison of the Efficacy and Safety of Sedation Drugs Used in a Pediatric Emergency Department
Principal Investigator: Mark G. Roback, MD
Co-Investigators: Joseph E. Wathen, MD, and Joan P. Bothner, MD
Term: 1999-ongoing

IV vs. IM Ketamine Sedation in the Pediatric Emergency Department
Principal Investigator: Mark G. Roback, MD
Co-Investigator: Joseph E. Wathen, MD
Source: The Children's Hospital Research Institute
Amount: $35,000
Term: 2000-ongoing

Pediatric Resuscitation Practice and Success Rate
Principal Investigator: Mark G. Roback, MD
Co-Investigator: Rebecca Fastle, MD
Term: 2000-ongoing

Predictors of Which Patients will Benefit from Observations vs. Hospital Admission
Principal Investigator: Genie E. Roosevelt, MD, MPH
Co-Investigator: S. Glenn Faries, MD
Term: 2002-ongoing

Randomized, Double-Blind Study of Intravenous Fluids With and Without Dextrose in the Treatment of Dehydration in Pediatric Patients with Vomiting and Ketosis
Principal Investigator: Genie E. Roosevelt, MD, MPH
Term: 2002-ongoing

The Effect of Dehydration on the QT Interval of Healthy Children
Principal Investigator: Carl Shaw, MD
Co-Investigators: Joseph E. Wathen, MD, and Michael S. Schaffer, MD
Term: 2001

The Prevalence of Urinary Tract Infections in Febrile Children with AGE
Principal Investigator: Carl Shaw, MD
Co-Investigator: Louis C. Hampers, MD, MBA
Term: 2002-ongoing

Use of Complementary Medicine in Pediatric Patients with Asthma
Principal Investigator: Alison Siegel Tothy, MD
Co-Investigator: Genie E. Roosevelt, MD, MPH
Term: 2001-2002

Associations between Insurance Type and Pediatric Admission Rate in Colorado, 1993-1999: Is Managed Care Fulfilling Its Promise?
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigators: Jill Joseph, MD, PhD, and James K. Todd, MD
Term: 2000-ongoing

Associations of Parental Depression and Child Health Outcomes
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigators: Allison Kempe, MD, John Steiner, MD, David Price, MD, and David Magid, MD
Term: 2002-ongoing

Comparison of the Longitudinal Marginal Cost, Morbidity and Mortality of Inflicted and Unintentional Head Injuries in Young Children in a Nationwide Sample of Children's Hospitals
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigator: Anne Libby, PhD
Term: 2001-ongoing

Costs of Childhood Physical Abuse: Comparing Inflicted and Unintentional Head Injuries in Colorado Inpatients Under Three Years Old
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigator: Anne Libby, PhD
Term: 2001-ongoing

Epidemiology of Pediatric Psychiatric Visits to US Emergency Departments, Based on the National Hospital Ambulatory Medical Care Survey 1995-1999
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigator: Shayne Bland, MSc
Term: 2001-ongoing

Hospital-Level Predictors of Inefficiency Amongst Hospitalized Patients in New York State
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigators: Jill Joseph, MD, PhD, and Andrew Racine, MD, PhD
Term: 2000-ongoing

Management of Acute Gastroenteritis Visits to Emergency Departments Based on the National Hospital Ambulatory Medical Care Survey, 1995-1999
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigator: Shayne Bland, MSc
Term: 2001-ongoing

Management of Bronchiolitis Visits to Emergency Departments Based on the National Hospital Ambulatory Medical Care Survey, 1993-1999
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigator: Shayne Bland, MSc
Term: 2001-ongoing

Comparison of Fascia Iliaca Compartment Nerve Block to Traditional Systemic Analgesics for Femur Fractures in a Pediatric Emergency Department
Principal Investigator: Joseph E. Wathen, MD
Co-Investigators: Glen Merritt, MD, Gaia Georgopoulos, MD, and F. Keith Battan, MD
Source: The Children's Hospital Research Institute
Amount: $17,594
Term: 2001-2004

Pediatric EKG Interpretation Accuracy by Pediatric Emergency Medicine Physicians
Principal Investigator: Joseph E. Wathen, MD
Co-Investigators: Arleta Rewers, MD, PhD, Angela Yetman MD, and Michael Schaffer MD
Term: 2001-ongoing

A Randomized Trial of Telephonic vs. On-Site Language Interpretation in a Pediatric ED
Principal Investigator: Ethan S. Wiener, MD
Co-Investigator: Louis C. Hampers, MD, MBA
Term: 2002-ongoing